NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
Priority Review
CIMDUO (lamivudine and tenofovir disoproxil fumarate) by Viatris (2) is nucleoside reverse transcriptase inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adult. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIMDUO is a fixed-dose combination of lamivudine and tenofovir disoproxil fumarate, two nucleoside reverse transcriptase inhibitors (NRTIs) used in combination with other antiretroviral agents to treat HIV-1 infection in adults. The drug works by inhibiting reverse transcriptase, an enzyme essential for HIV replication. It represents a convenient two-in-one oral tablet option for established HIV treatment.
$0.274MPart D
PeakProduct is in peak lifecycle with modest Part D utilization; modest team size expected with focus on market maintenance and adherence optimization.
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Career Relevance
CIMDUO is sponsored by Viatris, a global generic and branded specialty pharma company, offering career opportunities in commercial execution, market access, and global HIV treatment optimization. Roles tend to focus on brand management, health economics, and patient support programs rather than innovation pipelines.
Worked on CIMDUO at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.